Abstract: The invention provides a pharmaceutical for treatment of neurological and neuropsychiatric disorders comprising a compound of the formula: or a pharmaceutically acceptable salt thereof.

Abstract: The invention provides a pharmaceutical for treatment of neurological and neuropsychiatric disorders comprising a compound of the formula: or a pharmaceutically acceptable salt thereof.

Abstract: Cloning, expression, viral and delivery vectors and hosts which contain nucleic acid coding for at least one peripheral nervous system specific (PNS) sodium channel peptide (SCP), isolated PNS SCP, and compounds and compositions and methods, are provided, for isolating, crystallizing, x-ray analysing molecular modeling, rational drug designing, selecting, making and using therapeutic or diagnostic agents or ligands having at least one peripheral nervous system specific (PNS) sodium channel (SC) modulating activity.

Abstract: This invention provides isolated nucleic acid molecules encoding two mammalian GABA transporters, a mammalian taurine transporter and two human GABA transporters; methods of isolating these nucleic acid molecules and vectors comprising such nucleic acid molecules as well as mammalian cells comprising such vectors. Nucleic acid probes for detecting nucleic acid molecules encoding mammalian or human GABA transporters, or mammalian or human taurine transporters; antisense oligonucleotides complementary to any sequences of a nucleic acid molecule which encodes a mammalian GABA or taurine transporter or human GABA or taurine transporter; and antibodies to the mammalian GABA or taurine transporters, or human GABA or taurine transporters are provided. Pharmaceutical compounds related to mammalian GABA or taurine transporters and to human GABA or taurine transporters are provided.

Abstract: The invention provides a pharmaceutical for treatment of neurological and neuropsychiatric disorders comprising a compound of the formula: 1

Abstract: This invention provides isolated nucleic acid molecules encoding two mammalian GABA transporters, a mammalian taurine transporter and two human GABA transporters; methods of isolating these nucleic acid molecules and vectors comprising such nucleic acid molecules as well as mammalian cells comprising such vectors. Nucleic acid probes for detecting nucleic acid molecules encoding mammalian or human GABA transporters, or mammalian or human taurine transporters; antisense oligonucleotides complementary to any sequences of a nucleic acid molecule which encodes a mammalian GABA or taurine transporter or human GABA or taurine transporter; and antibodies to the mammalian GABA or taurine transporters, or human GABA or taurine transporters are provided. Pharmaceutical compounds related to mammalian GABA or taurine transporters and to human GABA or taurine transporters are provided.

Abstract: The invention provides a pharmaceutical for treatment of neurological and neuropsychiatric disorders comprising a compound of the formula: or a pharmaceutically acceptable salt thereof.

Abstract: This invention provides isolated nucleic acid molecules encoding a mammalian glycine transporter, isolated nucleic acid molecules encoding a human glycine transporter, isolated proteins which are mammalian glycine transporter proteins, isolated proteins which are human glycine transporter proteins, vectors comprising isolated nucleic acid molecules encoding a mammalian or a human glycine transporter, mammalian cells comprising such vectors, antibodies directed to a mammamlian glycine transporter, antibodies directed to a human glycine transporter, nucleic acid probes useful for detecting nucleic acid encoding mammalian glycine transporter, nucleic acid probes useful for detecting nucleic acid encoding human glycine transporter, antisense oligonucleotides complementary to any sequences of a nucleic acid molecule which encodes a mammalian glycine transporter, antisense oligonucleotides complementary to any sequences of a nucleic said molecule which encodes a human glycine transporter, pharmaceutical compounds r

Abstract: The invention provides a pharmaceutical for treatment of neurological and neuropsychiatric disorders comprising a compound of the following formulas I and II: ##STR1## or a pharmaceutically acceptable salt thereof.

Abstract: The present invention relates to materials and methods for the identification of agents that regulate glycine transport in or out of cells, particularly in or out of neuronal and neuronal-associated cells. Such materials include non-mammalian cells having transfected therein a glycine transporter. The methods relate to the manipulation of such cells such that agents are identified that cause intake or outflow of glycine with respect to a given glycine transporter.

Abstract: The invention provides nucleic acids and proteins derived from the sequence of the human GlyT-2 transporter of the amino acid glycine.

Abstract: The present invention relates to materials and methods for the identification of agents that regulate glycine transport in or out of cells, particularly in or out of neuronal and neuronal-associated cells. Such materials include non-mammalian cells having transfected therein a glycine transporter. The methods relate to the manipulation of such cells such that agents are identified that cause intake or outflow of glycine with respect to a given glycine transporter.

Abstract: This invention provides an isolated nucleic acid molecules encoding mammalian betaine/GABA transporters, including a human betaine/GABA transporter. This invention further provides vectors comprising said isolated nucleic acid molecules, and mammalian cells comprising such vectors. This invention further provides isolated mammalian and human betaine/GABA transporter proteins and antibodies directed thereto. This invention provides nucleic acid molecule probes useful for detecting nucleic acid molecules encoding mammalian or human betaine/GABA transporters, antisense oligonucleotides complementary to any sequences of a nucleic acid molecules which encode a mammalian or human betaine/GABA transporter. This invention further provides pharmaceutical compounds related to mammalian and human betaine/GABA transporters, and nonhuman transgenic animals which express DNA encoding a normal or a mutant mammalian or human betaine/GABA transporter.

Abstract: This invention provides isolated nucleic acid molecules encoding a mammalian glycine transporter, isolated nucleic acid molecules encoding a human glycine transporter, isolated proteins which are mammalian glycine transporter proteins, isolated proteins which are human glycine transporter proteins, vectors comprising isolated nucleic acid molecules encoding a mammalian or a human glycine transporter, mammalian cells comprising such vectors, antibodies directed to a mammalian glycine transporter, antibodies directed to a human glycine transporter, nucleic acid probes useful for detecting nucleic acid encoding mammalian glycine transporter, nucleic acid probes useful for detecting nucleic acid encoding human glycine transporter, antisense oligonucleotides complementary to any sequences of a nucleic acid molecule which encodes a mammalian glycine transporter, antisense oligonucleotides complementary to any sequences of a nucleic acid molecule which encodes a human glycine transporter, pharmaceutical compounds re

Abstract: This invention provides an isolated nucleic acid molecule encoding a mammalian betaine/GABA transporter, an isolated nucleic acid molecule encoding a human betaine/GABA transporter, an isolated protein which is a mammalian betaine/GABA transporter, an isolated protein which is a human betaine/GABA transporter, vectors comprising an isolated nucleic acid molecule encoding a mammalian betaine/GABA transporter, vectors comprising an isolated nucleic acid molecule encoding a human betaine/GABA transporter, mammalian cells comprising such vectors, antibodies directed to the mammalian betaine/GABA transporter and antibodies directed to the human betaine/GABA transporter, nucleic acid probes useful for detecting nucleic acid molecules encoding mammalian betaine/GABA transporters and human betaine/GABA transporters, antisense oligonucleotides complementary to any sequences of a nucleic acid molecule which encodes a mammalian betaine/GABA transporter or a human betaine/GABA transporter, pharmaceutical compounds relate

Abstract: This invention provides isolated nucleic acid molecules encoding two mammalian GABA transporters, a mammalian taurine transporter and two human GABA transporters and methods of isolating these nucleic acid molecules. Further provided are vectors comprising the nucleic acid molecules as well as mammalian cells comprising such vectors, and antibodies directed to the GABA and taurine transporters. Nucleic acid probes useful for detecting nucleic acid molecules encoding GABA and taurine transporters are also provided. Antisense oligonucleotides complementary to any sequences of a nucleic acid molecule which encodes a GABA or taurine transporter are further provided. Pharmaceutical compounds related to GABA and taurine transporters are provided. Nonhuman transgenic animals which express DNA encoding a normal or a mutant GABA or taurine transporter are also provided.